Qube Research & Technologies LTD Achilles Therapeutics PLC Call Options Transaction History
Qube Research & Technologies LTD
- $62.3 Billion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding ACHL
# of Institutions
29Shares Held
22.2MCall Options Held
0Put Options Held
0-
Syncona Portfolio LTD Guernsey, Channel Islands, X011.1MShares$10.4 Million10.58% of portfolio
-
Fcpm Iii Services B.V. Naarden, P72.39MShares$2.25 Million0.29% of portfolio
-
Redmile Group, LLC San Francisco, CA1.61MShares$1.51 Million0.09% of portfolio
-
Vestal Point Capital, LP New York, NY1.5MShares$1.41 Million0.09% of portfolio
-
Ikarian Capital, LLC Dallas, TX1.44MShares$1.36 Million0.48% of portfolio
About Achilles Therapeutics plc
- Ticker ACHL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 40,774,000
- Market Cap $38.3M
- Description
- Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in ...